BDNF-engineered regulatory T cells, a future regenerative cell-therapeutic strategy in progressive MS.

The general goal of this research project is to develop a clinically safe cell-based vaccine for the treatment of (progressive) MS, based on BDNF-expressing Tregs. By using state-of-the art techniques, we will develop "designer" Tregs that are engineered to express high levels of BDNF. We hypothesize that these Tregs will excel in their pro-regenerative properties, driving oligodendrocyte differentiation and remyelination, beyond immunomodulation with the aim to induce remyelination in MS.

Keywords:EXPERIMENTAL STUDY, REGENERATION CAPACITY

Disciplines:Applied immunology, Neurological and neuromuscular diseases, Cell therapy, Regenerative medicine not elsewhere classified